We also demonstrated that GIST patients may benefit from imatinib-targeted therapy due to TIME remodeling by tumor-infiltrating B cells in TLS, which were recruited by tumour-associated macrophages via the CXCR4-CXCL12 axis. This evidence concerns the gene CXCR4 and neoplasm.